Related Topics
 
Jeffery Klco, MD, PhD

Jeffery M. Klco, MD, PhD

Assistant Member, St. Jude Faculty

Departments

Pathology

Contact Information

Jeffery Klco, MD, PhD
Pathology
MS 342, Room D4047B
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: jeffery.klco@stjude.org
Phone: (901) 595-6807
FAX: (901) 595-5947

Education

MD, PhD - Washington University School of Medicine, St. Louis, MO
Resident Physician - Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO
Fellow - Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO
BS - Boston College, Boston, MA


Honors & Awards


Research interests


Selected Publications

Sarkaria SM, Christopher MJ, Klco JM, Ley TJ (2014). Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia 2014 (in press).

Klco JM*, Spencer DH*, Miller CA, Griffith M, Lamprecht TL, O’Laughlin M, Fronick C, Magrini V, Demeter RT, Fulton RS, Eades WC, Link DC, Graubert TA, Walter MJ, Mardis ER, Dipersio JF, Wilson RK, Ley TJ. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. *Authors contributed equally.Cancer Cell 25(3):379-92, 2014.

Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. NEJM 368(22):2059-74, 2013.

Grieselhuber NR*, Klco JM*, Verdoni AM, Lamprecht T, Sarkaria SM, WartmanLD, Ley TJ. Notch Signaling in Acute Promyelocytic Leukemia. *Authors contributed equally. Leukemia 27(7):1548-57, 2013.

Klco JM*, Spencer DH*, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N, Erdmann-Gilmore P, Lichti CF, Meyer MR, Townsend RR, Wilson RK, Mardis ER, Ley TJ. Genomic impact of transient low-dose decitabine treatment on primary AML cells. *Authors contributed equally. Blood 121(9):1633-43, 2013.

Wartman LD, Welch JS, Uy GL, Klco JM, Lamprecht T, Varghese N, Nagarajan R, Ley TJ. Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice. PLoS One 7(10), 2012.

Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, Kandoth C, Fulton RS, McLellan MD, Dooling DJ, Wallis JW, Chen K, Harris CC, Schmidt HK, Kalicki-Veizer JM, Lu C, Zhang Q, Lin L, O'Laughlin MD, McMichael JF, Delehaunty KD, Fulton LA, Magrini VJ, McGrath SD, Demeter RT, Vickery TL, Hundal J, Cook LL, Swift GW, Reed JP, Alldredge PA, Wylie TN, Walker JR, Watson MA, Heath SE, Shannon WD, Varghese N, Nagarajan R, Payton JE, Baty JD, Kulkarni S, Klco JM, Tomasson MH, Westervelt P, Walter MJ, Graubert TA, Dipersio JF, Ding L, Mardis ER, Wilson RK. The origin and evolution of mutations in acute myeloid leukemia. Cell (150):264-278, 2012.

Amador-Ortiz C, Hurley MY, Ghahramani GK, Frisch S, Klco JM, Lind AC, Nguyen TT, Hassan A, Kreisel FH, Frater JL. Use of classic and novel immunohistochemical markers in the diagnosis of cutaneous myeloid sarcoma. J Cutan Pathol (12):945-53, 2011.

WelchJS, Klco JM, GaoF, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study. Am J Hematol 86(9):796-800, 2011.

Klco JM, Welch JS, Nguyen TT, Hurley MY, Kreisel FH, Hassan A, Lind AC, Frater JL. State of the Art in Myeloid Sarcoma. Int J Lab Hematol 33(6):555-65, 2011.

Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, Wallis J, Chen K, Payton JE, Fulton RS, Veizer J, Schmidt H, Vickery TL, Heath S, Watson MA, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Ley TJ, Wilson RK. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305(15):1577-84, 2011.

Klco JM, Kulkarni S, Kreisel FH, Nguyen TT, Hassan A, Frater JL. Immunohistochemical analysis of monocytic leukemias: utility of CD14 and Krüppel-like factor 4, a novel monocyte marker. AJCP 135(5):720-30, 2011.

Wartman LD, Larson DE, Xiang Z, Ding L, Chen K, Lin L, Cahan P, Klco JM, Welch JS, Li C, Payton JE, Uy GL, Varghese N, Ries RE, Hoock M, Koboldt DC, McLellan MD, Schmidt H, Fulton RS, Abbott RM, Cook L, McGrath SD, Fan X, Dukes AF, Vickery T, Kalicki J, Lamprecht TL, Graubert TA, Tomasson MH, Mardis ER, Wilson RK, Ley TJ. Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J Clin Invest 121(4):1445-55, 2011.

Welch JS, Klco JM, Varghese N, Nagarajan R, Ley TJ. Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice. Blood 117:2460-8, 2011.

Capoccia BJ, Lennerz JK, Bredemeyer AJ, Klco JM, Frater JL, Mills JC. The transcription factor MIST1 in terminal differentiation of mouse and human plasma cells. Physiol Genomics 43(3):174-86, 2011.

Klco JM, Vij R, Kreisel FH, Hassan A, Frater JL. Molecular pathology of myeloproliferative neoplasms. Am J Clin Pathol 133(4):602-15, 2010.

Klco JM, Geng B, Brunt EM, Hassan A, Nguyen TD, Kreisel FH, Lisker-Melman M, Frater JL. Bone marrow biopsy in patients with hepatitis C virus infection: spectrum of findings and diagnostic utility. Am J Hematol 85(2):106-10, 2010.

Klco JM, Sen S, Hansen JL, Lyngsø C, Nikiforovich GV, Sheikh SP, Baranski TJ. Complement factor 5a receptor chimeras reveal the importance of lipid-facing residues in transport competence. FEBS J 276(10):2786-2800, 2009.

Klco JM, Kreisel FH, Zehnbauer BA, Kulkarni S, Hassan A, Frater JL. The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives. Am J Hematol 83:901-907, 2008.

Hagemann IS, Miller DL, Klco JM, Nikiforovich GV, Baranski TJ. Structure of the complement factor 5a receptor-ligand complex studied by disulfide trapping and molecular modeling. J Biol Chem 283(12):7763-75, 2008.

Klco JM, Nikiforovich GV, Baranski TJ. Genetic analysis of the first and third extracellular loops of the C5a receptor reveals an essential WxFG motif in the first loop. J Biol Chem 281:12010-12019, 2006.

Klco JM, Wiegand CB, Narzinski K, Baranski TJ. Essential role for the second extracellular loop in C5a receptor activation. Nat Struct Mol Biol 12:320-326, 2005.

Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG, Dervan PB. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A 101:16768-16773, 2004.

Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, Ohh M. pVHL Modification by NEDD8 is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development. Mol Cell Biol 24:3251-3261, 2004.

Klco JM, Lassere TB, Baranski TJ. C5a Receptor Oligomerization I: Disulfide Trapping Reveals Oligomers and Potential Contact Surfaces in a G Protein-coupled Receptor. J Biol Chem 278:35345-35353, 2003.

JiangY, Zhang W, Kondo K, Klco JM, St. Martin TB, Dufault MR, Madden SL, Kaelin WG Nacht M. Gene Expression Profiling in a Renal Cell Carcinoma Cell Line: Dissecting VHL and Hypoxia-Dependent Pathways. Mol Cancer Res 1:453-462, 2003.

Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG. Inhibition of HIF is Necessary for Tumor Suppression by the von Hippel-Lindau Protein. Cancer Cell 1:237-246, 2002.

Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG. von Hippel-Lindau Protein Mutants Linked to Type 2C VHL Disease Preserve the Ability to Downregulate HIF. Hum Mol Genet 10:1019-1027, 2001.

Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of Tumor Growth through Disruption of Hypoxia-inducible Transcription. Nat Med 6:1335-1340, 2000.

Last update: July 2014